Hints and tips:
...I think a lot of people were anticipating a V-shaped recovery . . . People are now waking up the realisation that volatility is going to be normal going forward.”...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...asked George Perry, neurobiology professor at the University of Texas San Antonio....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Mr Johnson argued that the home improvement trend had room to run....
...on Thursday after the ride-hailing company promised profitability in the final quarter of this year, officials in London and Washington told the FT that Donald Trump vented in “apoplectic” fury at Boris Johnson...
...“Fees are infinitesimally small because index funds have spawned competition hugely beneficial to the investor,” says Ben Johnson of Morningstar, the fund-ratings group....
...strong the feeling against Netflix at Cannes, there will be an opportunity to watch one film that will be distributed by the streamer: Wounds by Babak Anvari, a thriller that stars Armie Hammer and Dakota Johnson...
...“It’s not like the standard V-shaped recession in emerging markets, such as in Indonesia in 1998 where it’s only a year and a half of real economic hardship,” he said....
...The group behind the Les Paul, Flying V and Epiphone brands filed for Chapter 11 bankruptcy protection in May, overwhelmed by the debt it took on to fund an ill-fated diversification into headphones and...
...The artist Grayson Perry’s Brexit vases, which have gone on display in a different part of the V&A, offer a sophisticated variant of the same approach, drawing on crowd-sourced suggestions from Remainers...
...And Eddie Bernice Johnson, a Texas congresswoman, introduced a bill to fund the retraining of workers displaced by self-driving vehicles in a sign of the growing concern....
...Other big US drugmakers, including Johnson & Johnson, Merck and Amgen, would benefit in the same way from a so-called “inversion” with an overseas company and will be left at a disadvantage to Pfizer...
...Celltrion is seeking US approval for the drug along with its partner Hospira, which is being bought by Pfizer....
...Johnson & Johnson Johnson & Johnson has sat on the sidelines of the recent flurry of dealmaking, but it has been more open than most in signalling it is still on the hunt....
...Their new products will compete with Remicade, which is jointly owned by Merck and Johnson & Johnson of the US, and highlight the disruption facing the healthcare market by the arrival of lower-cost alternatives...
...Hospira was the first US company to launch a biosimilar in Europe last year with its version of the Remicade arthritis treatment shared by Johnson & Johnson and Merck & Co....
...Hospira was the first US company to launch a biosimilar with an imitation of Johnson & Johnson and Merck & Co’s Remicade arthritis drug, introduced in Europe last year....
...Johnson & Johnson, the world’s biggest maker of healthcare products, is exploring a deal with Pharmacyclics, one of the people said....
...It had made a $17bn deal to buy Hospira, a medical devices company, in February and was still searching for more assets to buy....
.... …………………………………………………………………………………………………………… Ben Hall, world news editor, picks: • Isis Inc: how oil fuels jihadi terrorists by Erika Solomon, Guy Chazan and Sam Jones• Why China’s ‘migrant miracle’ is...
...Further biosimilars are under consideration by the FDA, including a competitor for the Remicade arthritis drug owned by Johnson & Johnson and Merck....
...Additional reporting Miles Johnson...
...On March 2, the chief executives of Johnson & Johnson, Pfizer and AbbVie all rushed to California to make one last pitch to Pharmacyclics, a cancer drugmaker with just one product to its name....
...Chicago-based AbbVie made a late swoop to outbid Johnson & Johnson and a third rival with an offer of $261.25 per share in Pharmacyclics....
International Edition